Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10645229 | PMC |
| http://dx.doi.org/10.4103/aian.aian_425_23 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Clinical, electromyographic, and biophysical characterization of the rare Nav1.4 channel mutation L1436P.
Front Physiol
July 2025
Laboratory of Neurophysiology, GIGA Institute, University of Liège, Liège, Belgium.
Introduction: Our aims were to provide an integrated clinical and biophysical characterization of the rare variant NM_000334.4(SCN4A) c.4307T>C (p.
View Article and Find Full Text PDFDiscovery and Treatment of Action Potential-Independent Myotonia in Hyperkalemic Periodic Paralysis.
Ann Clin Transl Neurol
July 2025
Department of Neuroscience, Cell Biology and Physiology, Wright State University, Dayton, Ohio, USA.
Objective: Hyperkalemic periodic paralysis (hyperKPP) is characterized by attacks of transient weakness. A subset of hyperKPP patients suffers from transient involuntary contraction of muscle (myotonia). The goal of this study was to determine mechanisms causing myotonia in hyperKPP.
View Article and Find Full Text PDFImpaired aldosterone response to potassium and hyperkalemia in patients receiving a renin-angiotensin-aldosterone system inhibitor.
Korean J Intern Med
May 2025
Division of Nephrology, Department of Internal Medicine, Jeju National University Hospital, Jeju National University, School of Medicine, Jeju, Korea.
Background/aims: Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin II receptor blockers (ARBs) are associated with the development of hyperkalemia. We evaluated the relationship between the serum aldosterone-to-potassium ratio (APR) and the risk of developing hyperkalemia in patients with chronic kidney disease (CKD) receiving ACEIs or ARBs.
Methods: One hundred eighty-six patients with stage 3-4 CKD receiving an ACEI or ARB for at least 3 months were evaluated.
Clinical characteristics, treatment, and outcomes of hypoadrenocorticism in dogs.
J Small Anim Pract
September 2025
Department of Clinical Sciences, College of Veterinary Medicine, North Carolina State University, Raleigh, North Carolina, USA.
Objectives: To determine the long-term survival of dogs with hypoadrenocorticism during the period that desoxycorticosterone pivalate has become widely used. Secondary goals were to compare age at diagnosis, median survival times, and age at death for dogs with hyponatraemic and/or hyperkalaemic hypoadrenocorticism and eunatraemic eukalaemic hypoadrenocorticism, and to determine the frequency of glucocorticoid-related side effects in these dogs.
Materials And Methods: Retrospective cohort study with data collected from medical records and from a questionnaire sent to owners of affected dogs.
Effect of inhaled salbutamol on whole-blood potassium concentrations in healthy cats.
J Feline Med Surg
April 2025
Department of Clinical Sciences, Faculty of Veterinary Medicine, Université de Montréal, QC, Canada.
ObjectivesThis study aimed to determine the effect of inhaled salbutamol on blood potassium concentrations in normokalemic cats, evaluate whether effects are dose dependent and assess whether it affects heart rate and blood glucose concentrations.MethodsThe study was a prospective, open-label, two-way crossover trial. A total of 11 healthy cats were randomly assigned to two groups: one received a low dose of 100 µg salbutamol (Low group) and the other a high dose of 200 µg (High group).
View Article and Find Full Text PDF